Loading
If the ADC-immunotherapy combination erases the tumour in more than half of patients before surgery, some may not need their bladder removed at all.
pCR 57% in EV-303 and high pCR in EV-304 raise the question that dostarlimab answered in dMMR rectal cancer: can complete responders skip surgery? Trials (e.g., SunRISe-4 arms, MODERN, and investigator-led bladder-sparing studies) are beginning to test cystectomy omission with ctDNA and MRI-guided surveillance.
Almost every patient newly diagnosed with advanced bladder or urothelial cancer should now be offered enfortumab vedotin plus pembrolizumab rather than chemotherapy, with median survival extended from about 16 months to over two and a half years. Neuropathy and skin toxicity need monitoring and dose adjustment, and patients with severe diabetes or pre-existing neuropathy need care. Platinum chemotherapy remains an option for those who cannot receive the combination.
One of the most cited trial reports Europe PMC returns for Pembrolizumab in Bladder & urothelial cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Pembrolizumab in Bladder & urothelial cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares EV-304 / KEYNOTE-B15, EV-303 / KEYNOTE-905, Enfortumab vedotin, Bladder & urothelial cancer.
Shares EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
Shares EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer, Enfortumab vedotin, Signatera, MRD / molecular residual disease testing.
Shares EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer, Enfortumab vedotin, Bladder & urothelial cancer.
Shares EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.